Medplus Q3 FY26 Earnings Call Transcript Released
Medplus Health Services Limited released its Q3 FY26 earnings call transcript. The company added 182 net stores in the quarter, reaching 5,112 total stores. Consolidated revenue was ₹18,061 million, with operating EBITDA at ₹96.8 crore. Pharmacy revenue grew 15.6% YoY. Private label sales were 22.2% of total revenue.
The earnings call transcript provides detailed financial and operational performance data for the quarter, including store expansion, revenue, and profitability metrics. This information is material for investors and analysts assessing the company's performance and outlook.
The announcement is a transcript of an earnings call, which is a routine disclosure of financial results and operational updates. While the results discussed were generally positive, the nature of the announcement itself is neutral.
MedPlus Health Services Limited has released the transcript of its Earnings Call held on February 02, 2026, to discuss the financial results for the third quarter of FY26, ending December 31, 2025.
The company reported a net addition of 182 stores during the quarter, contributing to a total of 400 net additions in the current financial year, with a target of adding 600 new stores in FY26. The store network grew to 5,112 stores.
Consolidated revenue for the quarter stood at ₹18,061 million. Consolidated operating EBITDA was ₹96.8 crore (5.4%), after considering a non-recurring charge of ₹7.059 crore related to the implementation of the new Labour Code. Pharmacy operations revenue grew by 15.6% year-on-year, with pharmacy operating EBITDA at ₹92.5 crore (5.2%).
Private label sales constituted 22.2% of total revenues (11.6% Pharma, 10.6% FMCG). On a GMV basis, private label pharma sales were 18.9% of total sales.
Stores older than 12 months generated revenue of ₹16,300 million (96% of pharmacy revenues) with a store-level EBITDA margin of 12.4%. Diagnostics revenue grew to ₹326.7 million, with an operating EBITDA of ₹50.7 million (15.5% margin).
The company discussed strategies to drive Same-Store Sales Growth (SSSG), including adjustments to the store-level incentive structure to encourage total sales growth. They also provided insights into the margin profiles of branded vs. private label products across pharma and non-pharma categories. The company indicated that gross margins are expected to remain stable, and they are exploring franchisee models.
Regarding future outlook, the company aims to continue store expansion, targeting similar numbers to the current year for FY27. They are also focused on improving operating leverage and private label penetration, particularly in the non-pharma segment, to enhance profitability.
What to do with a filing like this
Medplus Health Services Limited filed this with the NSE as a statutory disclosure, categorised under concall transcript released. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Medplus Health Services Limited. Read the original for the full detail.